---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040784"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:15:37.368738+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix posts $458K Q3 revenue; CMS reimbursement request not approved

## Summary
- Q3 2023 revenue of $458,000; operating loss of $670,000; year-to-date revenue up 22%, operating loss reduced ~20%.
- Raised $4.2M net from securities sales; cash & receivables $3.8M, inventory >$3.1M.
- UK NHS supply contract and Drug Tariff reimbursement effective Nov 1; UK distributor Peak Medical pursuing opportunities.
- Added Mio-Guard as exclusive distributor for Sports segment; VA and Workers Comp channels progressing.
- CMS denied full reimbursement again after August 2023 notification; company awaiting response after meeting with CMS leadership.

## SEC filing metadata
- accession: 0001493152-23-040784
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315223040784/0001493152-23-040784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315223040784/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040784
- JSON: https://secwatch.observer/filing/0001493152-23-040784.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.